Publications
- Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry2025 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Frontiers in Oncology Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML2025 | First Faculty of Medicine
- Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL2024 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Current targeted therapy options in chronic lymphocytic leukemia2024 | First Faculty of Medicine
- Rituximab-venetoclax in the second line of treatment of chronic lymphocytic leukemia in a patient with TP53 mutation2024 | First Faculty of Medicine
- Venetoklax v první linii terapie chronické lymfocytární leukemie2024 | First Faculty of Medicine
- Interna pro bakalářské a magisterské obory2024 | First Faculty of Medicine
- Acta Medicinae Minimální/měřitelná reziduální nemoc u krevních nádorových onemocnění v roce 20242024 | First Faculty of Medicine
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University
Loading network view...
